153 related articles for article (PubMed ID: 28801995)
21. A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary.
Carlson H; Lenzi R; Raber MN; Varadhachary GR
Int J Clin Oncol; 2013 Apr; 18(2):226-31. PubMed ID: 22218909
[TBL] [Abstract][Full Text] [Related]
22. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
Kuhlmann JB; Euringer W; Spangenberg HC; Breidert M; Blum HE; Harder J; Fischer R
Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):437-43. PubMed ID: 22261548
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
Jang JS; Lim HY; Hwang IG; Song HS; Yoo N; Yoon S; Kim YH; Park E; Byun JH; Lee MA; Oh SJ; Lee KH; Kim BS; Oh SC; Kim SY; Lee SJ
Cancer Chemother Pharmacol; 2010 Mar; 65(4):641-7. PubMed ID: 19652971
[TBL] [Abstract][Full Text] [Related]
24. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B
Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200
[TBL] [Abstract][Full Text] [Related]
25. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katopodis O; Souglakos J; Stathopoulos E; Christopoulou A; Kontopodis E; Kotsakis A; Kalbakis K; Kentepozidis N; Polyzos A; Hatzidaki D; Georgoulias V
Cancer Chemother Pharmacol; 2014 Aug; 74(2):333-40. PubMed ID: 24930058
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C;
Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer.
Sharma A; Mohanti B; Raina V; Shukla N; Pal S; Dwary A; Deo S; Sahni P; Garg P; Thulkar S; DattaGupta S; Rath G
Cancer Chemother Pharmacol; 2010 Feb; 65(3):497-502. PubMed ID: 19575200
[TBL] [Abstract][Full Text] [Related]
28. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
[TBL] [Abstract][Full Text] [Related]
29. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC
Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies.
He L; Deng H; Lei J; Yi F; Li J; Fan X; Wei Y; Xu J; Zhang W
BMC Cancer; 2019 Mar; 19(1):276. PubMed ID: 30922256
[TBL] [Abstract][Full Text] [Related]
32. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
Williet N; Dubreuil O; Boussaha T; Trouilloud I; Landi B; Housset M; Botti M; Rougier P; Belghiti J; Taieb J
World J Gastroenterol; 2011 May; 17(17):2255-8. PubMed ID: 21633538
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
Elshebeiny M; Almorsy W
J Egypt Natl Canc Inst; 2016 Sep; 28(3):183-9. PubMed ID: 27237370
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.
Yang TS; Wang CH; Hsieh RK; Chen JS; Fung MC
Ann Oncol; 2002 Nov; 13(11):1771-8. PubMed ID: 12419750
[TBL] [Abstract][Full Text] [Related]
37. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Raftery L; Tepper JE; Goldberg RM; Blackstock AW; Aklilu M; Bernard SA; Ivanova A; Davies JM; O'Neil BH
Am J Clin Oncol; 2013 Jun; 36(3):250-3. PubMed ID: 22547007
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
He SL; Shen J; Sun XJ; Zhu XJ; Liu LM; Dong JC
World J Gastroenterol; 2013 Jul; 19(28):4552-8. PubMed ID: 23901232
[TBL] [Abstract][Full Text] [Related]
39. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.
Steer CB; Chrystal K; Cheong KA; Galani E; Marx GM; Strickland AH; Yip D; Lofts F; Gallagher C; Thomas H; Harper PG
Gynecol Oncol; 2006 Nov; 103(2):439-45. PubMed ID: 16643993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
